Filing Flows › RenovoRx (RNXT) › R&D spending
RenovoRx (RNXT) R&D spending by quarter
RenovoRx's R&D spending was $1.2M in Q3 2026 (third quarter 2026), +3% from Q2 2026. Over the last 7 quarters it ranged from $1.2M (Q2 2026) to $1.7M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.2M | +3% | -26% |
| Q2 2026 | $1.2M | -2% | -16% |
| Q1 2026 | $1.2M | -18% | -25% |
| Q4 2025 | $1.5M | -11% | — |
| Q3 2025 | $1.7M | +18% | — |
| Q2 2025 | $1.4M | -13% | — |
| Q1 2025 | $1.6M | — | — |
Q3 2026 at a glance
RenovoRx, Q3 2026: revenue $1.1M (+301% year over year), operating margin -303.6%, net loss $3.6M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is RenovoRx's R&D spending?
RenovoRx's R&D spending was $1.2M in Q3 2026 (third quarter 2026), +3% from Q2 2026.
How has RenovoRx's R&D spending changed?
Over the last 7 quarters it ranged from $1.2M (Q2 2026) to $1.7M (Q3 2025).